InvestorsClick here for Proxy Materials and Annual Meeting Information
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. Alnylam is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers.
|There are currently no items available.|
Alnylam Announces Closing of Previously Announced Acquisition of Merck’s Sirna Therapeutics Subsidiary
|CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2014--
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced today that the previously announced acquisition of
Merck’s wholly owned subsidiary Sirna Therapeutics, Inc. (“Sirna
Therapeutics” or “Sirna”) has closed, following the expiration of the
Hart-Scott-Rodino waiting period. On January 10, 2014, Alnylam entered
into a stock purchase agreement with Merck pursuant... |
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.